Motavizumab for the prevention of respiratory syncytial virus infection in infants

Bibliography

• Heilman CA. From the national institute of allergy and infectious diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990;161(3):402-6
   PubMed Web of Science ®Google Scholar
• Respiratory syncytial virus activity–United States, 1999-2000 season. MMWR Morb Mortal Wkly Rep 2000;49(48):1091-3
   PubMedGoogle Scholar
• Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child (1960) 1986;140(6):543-6
   PubMedGoogle Scholar
• Falsey AR, Formica MA, Hennessey PA, et al. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173(6):639-43
   PubMed Web of Science ®Google Scholar
• Ackerman BD. Acute bronchiolitis: a study of 207 cases. Clin Pediatr (Phila) 1962;1:75-81
   PubMedGoogle Scholar
• Chanock RM, Kim HW, Vargosko AJ, et al. Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children. JAMA 1961;176:647-53
   PubMed Web of Science ®Google Scholar
• Holberg CJ, Wright AL, Martinez FD, et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991;133(11):1135-51
   PubMed Web of Science ®Google Scholar
• Boyce TG, Mellen BG, Mitchel EF Jr, et al. Rates of hospitalization for respiratory syncytial virus infection among children in medicaid. J Pediatr 2000;137(6):865-70
   PubMed Web of Science ®Google Scholar
• Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981;98(5):708-15
   PubMed Web of Science ®Google Scholar
• Leader S, Kohlhase K. Respiratory syncytial virus-coded pediatric hospitalizations, 1997 to 1999. Pediatr Infect Dis J 2002;21(7):629-32
   PubMed Web of Science ®Google Scholar
• Shay DK, Holman RC, Roosevelt GE, et al. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001;183(1):16-22
   PubMed Web of Science ®Google Scholar
• Acute Respiratory Infections (Update 2009). World Health Organization: Initiative for Vaccine Research (IVR). Geneva, Switzerland; 2009. Available from: http://www.who.int/vaccine_research/diseases/ari/en/.
   Google Scholar
• Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360(6):588-98
   PubMed Web of Science ®Google Scholar
• Pelletier AJ, Mansbach JM, Camargo CA Jr. Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics 2006;118(6):2418-23
   PubMed Web of Science ®Google Scholar
• Yusuf S, Piedimonte G, Auais A, et al. The relationship of meteorological conditions to the epidemic activity of respiratory syncytial virus. Epidemiol Infect 2007;135(7):1077-90
   PubMed Web of Science ®Google Scholar
• Dobson JV, Stephens-Groff SM, McMahon SR, et al. The use of albuterol in hospitalized infants with bronchiolitis. Pediatrics 1998;101(3 Pt 1):361-8
   PubMed Web of Science ®Google Scholar
• Corneli HM, Zorc JJ, Mahajan P, et al. A multicenter, randomized, controlled trial of dexamethasone for bronchiolitis. N Engl J Med 2007;357(4):331-9
   PubMed Web of Science ®Google Scholar
• Levine DA, Platt SL, Dayan PS, et al. Risk of serious bacterial infection in young febrile infants with respiratory syncytial virus infections. Pediatrics 2004;113(6):1728-34
   PubMed Web of Science ®Google Scholar
• Hammer J, Numa A, Newth CJ. Albuterol responsiveness in infants with respiratory failure caused by respiratory syncytial virus infection. J Pediatr 1995;127(3):485-90
   PubMed Web of Science ®Google Scholar
• Schuh S, Canny G, Reisman JJ, et al. Nebulized albuterol in acute bronchiolitis. J Pediatr 1990;117(4):633-7
   PubMed Web of Science ®Google Scholar
• Gadomski AM, Lichenstein R, Horton L, et al. Efficacy of albuterol in the management of bronchiolitis. Pediatrics 1994;93(6 Pt 1):907-12
   PubMed Web of Science ®Google Scholar
• Dabbous IA, Tkachyk JS, Stamm SJ. A double blind study on the effects of corticosteroids in the treatment of bronchiolitis. Pediatrics 1966;37(3):477-84
   PubMed Web of Science ®Google Scholar
• Roosevelt G, Sheehan K, Grupp-Phelan J, et al. Dexamethasone in bronchiolitis: a randomised controlled trial. Lancet 1996;348(9023):292-5
   PubMed Web of Science ®Google Scholar
• Leer JA Jr, Green JL, Heimlich EM, et al. Corticosteroid treatment in bronchiolitis. A controlled, collaborative study in 297 infants and children. Am J Dis Child (1960) 1969;117(5):495-503
   PubMedGoogle Scholar
• Flores G, Horwitz RI. Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis. Pediatrics 1997;100(2 Pt 1):233-9
   PubMed Web of Science ®Google Scholar
• American academy of pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis management of bronchiolitis. Pediatrics 2006;118(4):1774-93
   PubMed Web of Science ®Google Scholar
• Welliver TP, Garofalo RP, Hosakote Y, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007;195(8):1126-36
   PubMed Web of Science ®Google Scholar
• Hall CB, McBride JT, Walsh EE, et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983;308(24):1443-7
   PubMed Web of Science ®Google Scholar
• Rodriguez WJ, Hall CB, Welliver R, et al. Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial. J Pediatr 1994;125(1):129-35
   PubMed Web of Science ®Google Scholar
• Smith DW, Frankel LR, Mathers LH, et al. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991;325(1):24-9
   PubMed Web of Science ®Google Scholar
• Moler FW, Bandy KP, Custer JR. Ribavirin therapy for acute bronchiolitis: need for appropriate controls. J Pediatr 1991;119(3):509-10
   PubMedGoogle Scholar
• Safety Study of Oral BTA9881 to Treat RSV Infection. 2007 Available from: http://clinicaltrials.gov/ct2/show/NCT00504907 [Cited 18 July 2007]
   Google Scholar
• Cianci C, Yu KL, Combrink K, et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob Agents Chemother 2004;48(2):413-22
   PubMed Web of Science ®Google Scholar
• Bonfanti JF, Roymans D. Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection. Curr Opin Drug Discov Devel 2009;12(4):479-87
   PubMed Web of Science ®Google Scholar
• Kim HW, Canchola JG, Brandt CD, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969;89(4):422-34
   PubMed Web of Science ®Google Scholar
• Tristram DA, Welliver RC, Mohar CK, et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993;167(1):191-5
   PubMed Web of Science ®Google Scholar
• Gonzalez IM, Karron RA, Eichelberger M, et al. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 2000;18(17):1763-72
   PubMed Web of Science ®Google Scholar
• Groothuis JR, Simoes EA, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993;329(21):1524-30
   PubMed Web of Science ®Google Scholar
• Welliver RC. Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection. Semin Perinatol 1998;22(1):87-95
   PubMed Web of Science ®Google Scholar
• Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998;102(3 Pt 1):531-7
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner HC, et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143(4):532-40
   PubMed Web of Science ®Google Scholar
• Pickering LK, Baker CJ, Long SS, McMillan JA, editors, Red Book: 2009 Report of the Committee on Infectious Diseases. 28th edition. Elk Grove Villiage, IL: American Academy of Pediatrics; 2009
   Google Scholar
• Rodriguez WJ, Gruber WC, Groothuis JR, et al. Respiratory syncytial virus immune globulin treatment of RSV lower respiratory tract infection in previously healthy children. Pediatrics 1997;100(6):937-42
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Moreno MT, Ramilo O, et al. Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection. Pediatr Infect Dis J 2004;23(8):707-12
   PubMed Web of Science ®Google Scholar
• Wu H, Pfarr DS, Johnson S, et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007;368(3):652-65
   PubMed Web of Science ®Google Scholar
• Abarca K, Jung E, Fernandez P, et al. Safety, tolerability, pharmacokinetics, and immunogenicity of motavizumab, a humanized, enhanced-potency monoclonal antibody for the prevention of respiratory syncytial virus infection in at-risk children. Pediatr Infect Dis J 2009;28(4):267-72
   PubMed Web of Science ®Google Scholar
• Carbonell X, Losonsky GA, Micki H, Edward C. Phase 3 trial of motavizumab (MEDI-524), an enhanced potency respiratory syncytial virus (RSV) specific monoclonal antibody (Mab) for the prevention of serious RSV disease in high risk infants. Abstract presented at annual PAS meeting in Toronto, Canada. E-PAS2007:6182209 2007 May 1-4, 2007
   Google Scholar
• HPTN 057 SSP Manual, Section 11. Adverse Event Reporting and Safety Monitoring. 2007:1-11. Available from: http://www.hptn.org/ web%20documents/HPTN057/SSP/HPTN057Section11AEsv3.0FINAL.pdf
   Google Scholar
• Wilkesmann A, Ammann RA, Schildgen O, et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr Infect Dis J 2007;26(6):485-91
   PubMed Web of Science ®Google Scholar
• Chanock RM, Parrott RH, Connors M, et al. Serious respiratory tract disease caused by respiratory syncytial virus: prospects for improved therapy and effective immunization. Pediatrics 1992;90(1 Pt 2):137-43
   PubMed Web of Science ®Google Scholar
• Polack FP, Teng MN, Collins PL, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002;196(6):859-65
   PubMed Web of Science ®Google Scholar
• Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976;134(3):211-7
   PubMed Web of Science ®Google Scholar
• Meert KL, Sarnaik AP, Gelmini MJ, Lieh-Lai MW. Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial. Crit Care Med 1994;22(4):566-72
   PubMed Web of Science ®Google Scholar
• Randolph AG, Wang EE. Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview. Arch Pediatr Adolesc Med 1996;150(9):942-7
   PubMed Web of Science ®Google Scholar
• Merkus PJ, de Hoog M, van Gent R, de Jongste JC. DNase treatment for atelectasis in infants with severe respiratory syncytial virus bronchiolitis. Eur Respir J 2001;18(4):734-7
   PubMed Web of Science ®Google Scholar
• Hollman G, Shen G, Zeng L, et al. Helium-oxygen improves Clinical Asthma Scores in children with acute bronchiolitis. Crit Care Med 1998;26(10):1731-6
   PubMed Web of Science ®Google Scholar
• Liet JM, Millotte B, Tucci M, et al. Noninvasive therapy with helium-oxygen for severe bronchiolitis. J Pediatr 2005;147(6):812-7
   PubMed Web of Science ®Google Scholar
• Broughton S, Greenough A. Effectiveness of drug therapies to treat or prevent respiratory syncytial virus infection-related morbidity. Expert Opin Pharmacother 2003;4(10):1801-8
   PubMed Web of Science ®Google Scholar
• Patel NR, Hammer J, Nichani S, et al. Effect of inhaled nitric oxide on respiratory mechanics in ventilated infants with RSV bronchiolitis. Intensive Care Med 1999;25(1):81-7
   PubMed Web of Science ®Google Scholar
• Neuzil KM, Gruber WC, Chytil F, et al. Safety and pharmacokinetics of vitamin A therapy for infants with respiratory syncytial virus infections. Antimicrob Agents Chemother 1995;39(5):1191-3
   PubMed Web of Science ®Google Scholar
• Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998;178(6):1555-61
   PubMed Web of Science ®Google Scholar
• Mandelberg A, Tal G, Witzling M, et al. Nebulized 3% hypertonic saline solution treatment in hospitalized infants with viral bronchiolitis. Chest 2003;123(2):481-7
   PubMed Web of Science ®Google Scholar
• Kuzik BA, Al-Qadhi SA, Kent S, et al. Nebulized hypertonic saline in the treatment of viral bronchiolitis in infants. J Pediatr 2007;151(3):266-70, 70 e1
   PubMed Web of Science ®Google Scholar
• Tibby SM, Hatherill M, Wright SM, et al. Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis. Am J Respir Crit Care Med 2000;162(4 Pt 1):1251-6
   PubMed Web of Science ®Google Scholar
• Bisgaard H, Flores-Nunez A, Goh A, et al. Study of montelukast for the treatment of respiratory symptoms of post-respiratory syncytial virus bronchiolitis in children. Am J Respir Crit Care Med 2008;178(8):854-60
   PubMed Web of Science ®Google Scholar